Mainz Biomed (MYNZ) announced that its test ColoAlert has been added to the portfolio of DoctorBox. This marks another important milestone in Mainz Biomed’s European growth strategy and highlights the increasing importance of innovative, personalized solutions in preventive medicine. Laboratory analysis will be performed by Mainz Biomed’s long-standing partner, the European Oncology Lab, led by Dr. med. Annette Buhlmann in St. Ingbert, Germany.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYNZ:
- Mainz Biomed B.V. Amends Articles to Boost Share Capital
- Mainz Biomed, OncoVanguard8 agree to bring ColoAlert to South America
- Mainz Biomed’s Colorectal Cancer Test: A Promising Pilot Study Update
- Mainz Biomed’s Colorectal Cancer Screening Test: A New Hope for Early Detection
- Promising Diagnostic Advances and Strategic Collaborations Justify Buy Rating for Mainz Biomed